X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs FULFORD INDIA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE FULFORD INDIA CADILA HEALTHCARE/
FULFORD INDIA
 
P/E (TTM) x 23.3 398.8 5.9% View Chart
P/BV x 5.9 6.2 94.3% View Chart
Dividend Yield % 0.8 0.1 948.4%  

Financials

 CADILA HEALTHCARE   FULFORD INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
FULFORD INDIA
Mar-14
CADILA HEALTHCARE/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs460942 48.8%   
Low Rs305450 67.8%   
Sales per share (Unadj.) Rs92.1691.4 13.3%  
Earnings per share (Unadj.) Rs14.811.5 129.3%  
Cash flow per share (Unadj.) Rs18.515.4 120.3%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.3 291.1%  
Book value per share (Unadj.) Rs68.0380.0 17.9%  
Shares outstanding (eoy) m1,023.743.90 26,249.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.0 412.5%   
Avg P/E ratio x25.860.7 42.5%  
P/CF ratio (eoy) x20.745.3 45.7%  
Price / Book Value ratio x5.61.8 307.2%  
Dividend payout %21.617.4 123.8%   
Avg Mkt Cap Rs m391,5812,714 14,426.0%   
No. of employees `00016.90.4 3,796.2%   
Total wages/salary Rs m15,002505 2,970.7%   
Avg. sales/employee Rs Th5,594.56,073.0 92.1%   
Avg. wages/employee Rs Th890.11,137.4 78.3%   
Avg. net profit/employee Rs Th899.9100.7 893.9%   
INCOME DATA
Net Sales Rs m94,2952,696 3,497.1%  
Other income Rs m1,286125 1,025.5%   
Total revenues Rs m95,5812,822 3,387.2%   
Gross profit Rs m19,036-46 -41,025.9%  
Depreciation Rs m3,75015 24,671.1%   
Interest Rs m45010 4,736.8%   
Profit before tax Rs m16,12254 29,690.6%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,28910 13,427.1%   
Profit after tax Rs m15,16845 33,932.9%  
Gross profit margin %20.2-1.7 -1,173.1%  
Effective tax rate %8.017.7 45.2%   
Net profit margin %16.11.7 970.3%  
BALANCE SHEET DATA
Current assets Rs m60,2231,738 3,464.5%   
Current liabilities Rs m53,058545 9,740.8%   
Net working cap to sales %7.644.3 17.2%  
Current ratio x1.13.2 35.6%  
Inventory Days Days7048 144.1%  
Debtors Days Days884 2,048.0%  
Net fixed assets Rs m72,98412 613,310.9%   
Share capital Rs m1,02439 2,625.6%   
"Free" reserves Rs m68,5761,443 4,752.3%   
Net worth Rs m69,6001,482 4,696.4%   
Long term debt Rs m24,6840-   
Total assets Rs m152,2072,077 7,329.3%  
Interest coverage x36.86.7 548.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.61.3 47.7%   
Return on assets %10.32.6 393.2%  
Return on equity %21.83.0 722.5%  
Return on capital %17.94.3 416.5%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m21,28017 123,720.9%   
Fx outflow Rs m10,874673 1,615.4%   
Net fx Rs m10,406-656 -1,586.4%   
CASH FLOW
From Operations Rs m13,49590 14,994.4%  
From Investments Rs m-29,103105 -27,823.1%  
From Financial Activity Rs m23,158-14 -164,241.1%  
Net Cashflow Rs m7,556181 4,186.1%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 3.8 218.4%  
FIIs % 5.9 0.1 5,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.2 51.9%  
Shareholders   44,069 4,783 921.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 15, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS